Small Molecules
2 December 2014
ABIVAX Successfully Completes First-in-man Study of ABX464, a Highly Differentiated Small Molecule Targeting HIV2 December 2014
Actelion submits selexipag (Uptravi) for EMA Marketing Authorisation in patients with pulmonary arterial hypertension2 December 2014
Sanofi Receives FDA Approval of Priftin® (rifapentine) Tablets for the Treatment of Latent Tuberculosis Infection1 December 2014
Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere’s Disease1 December 2014
Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers1 December 2014
Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS)1 December 2014
Eli Lilly and Company and AstraZeneca Initiate Pivotal Clinical Trial for Patients with Early Alzheimer’s Disease28 November 2014
Novartis’ heart failure medicine LCZ696 granted accelerated assessment by CHMP in Europe[1]27 November 2014
Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy27 November 2014
Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA25 November 2014
European Commission Approves REZOLSTA, A New Once-Daily, Fixed-Dose HIV Therapy Combining Darunavir And Cobicistat25 November 2014
Intra-Cellular Therapies Announces Enrollment of First Patient in Phase 3 Trial of ITI-007 for the Treatment of Schizophrenia25 November 2014
Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON™ Gel For The Treatment Of Acne Vulgaris25 November 2014
Janssen Submits New Drug Application for YONDELIS® (trabectedin) to U.S. FDA for the Treatment of Patients with Advanced Soft Tissue Sarcoma24 November 2014
FDA Grants QIDP Designation to Bayer’s Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation24 November 2014
Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients24 November 2014
Galapagos completes recruitment for Darwin 2 monotherapy study with GLPG0634 (filgotinib) in RA24 November 2014
Crossject Reports Positive Results From Bioequivalence Study With Needle Free ZENEO® Methrotrexate24 November 2014
Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment24 November 2014
Duaklir® Genuair® approved in the European Union for chronic obstructive pulmonary disease22 November 2014
ZS Pharma Announces Publication of Results From Phase 3 Study of ZS-9 in Patients With Hyperkalemia in the New England Journal of MedicineNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports